Get started
Author

L. Arthur Hewitt

Observed names: Hewitt, L., Hewitt, Lawrence Arthur, L A Hewitt, L HEWITT, L. ARTHUR HEWITT, L. Hewitt, L.A. Hewitt, Lawrence A Hewitt, Lawrence Arthur Hewitt, Lawrence Hewitt
Observed institutions: Mount Sinai Hospital, Beth Israel Deaconess Medical Center, Mayo Clinic, Lundbeck (Denmark), University of Toronto, Vanderbilt University, University of South Florida, St Mary's Hospital Centre, NYU Langone Health, Amgen (Canada), Abbott (Canada), Lundbeck (United States), UCL Queen Square Institute of Neurology, University College London, Imperial College London, Monash University, New York University, Université de Montréal, Vanderbilt University Medical Center
ORCID: 0000-0003-1201-842X
Observed ORCID: 0000-0003-1201-842X
OpenAlex ID: A5066586159
Droxidopa for neurogenic orthostatic hypotension
2014 · Horacio Kaufmann, Roy Freeman, et al. · Neurology · 279
PDF
Droxidopa for the S hort‐ T erm T reatment of S ymptomatic N eurogenic O rthostatic H ypotension in P arkinson's D isease (n OH 306 B )
2014 · Robert A. Hauser, Stuart Isaacson, et al. · Movement Disorders · 148
Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa
2014 · Italo Biaggioni, Roy Freeman, et al. · Hypertension · 145
Droxidopa in Patients with Neurogenic Orthostatic Hypotension Associated with Parkinson's Disease (NOH306A)
2014 · Robert A. Hauser, L. Arthur Hewitt, et al. · Journal of Parkinson s Disease · 97
PDF
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
2017 · Italo Biaggioni, L. Arthur Hewitt, et al. · BMC Neurology · 81
PDF
Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension
2016 · Robert A. Hauser, Stephane Heritier, et al. · Clinical Neuropharmacology · 64
Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers
2018 · Daniel O. Claassen, Charles H. Adler, et al. · BMC Neurology · 48
PDF
Temporal relationships between biotransformation, detoxication, and chlordecone potentiation of chloroform-induced hepatotoxicity
1986 · L. Arthur Hewitt, Gilles Caillé, et al. · Canadian Journal of Physiology and Pharmacology · 27
Fractional hepatic localization of 14CHCl3 in mice and rats treated with chlordecone or mirex
1983 · L HEWITT, W HEWITT, et al. · Fundamental and Applied Toxicology · 25
Effects of the novel norepinephrine prodrug, droxidopa, on ambulatory blood pressure in patients with neurogenic orthostatic hypotension
2016 · Horacio Kaufmann, Lucy Norcliffe-Kaufmann, et al. · Journal of the American Society of Hypertension · 23
Modifications in rat hepatobiliary function following treatment with acetone, 2-butanone, 2-hexanone, mirex, or chlordecone and subsequently exposed to chloroform*1, *2
1986 · L HEWITT · Toxicology and Applied Pharmacology · 23
Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease
2018 · Robert A. Hauser, Italo Biaggioni, et al. · Movement Disorders Clinical Practice · 19
PDF
Dose-response relationships in 1,3-butanediol-induced potentiation of carbon tetrachloride toxicity
1982 · William R. Hewitt, Hiroaki Miyajima, et al. · Toxicology and Applied Pharmacology · 19
Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension
2017 · William B. White, Robert A. Hauser, et al. · The American Journal of Cardiology · 18
PDF
Evidence for the involvement of organelles in the mechanism of ketone‐potentiated chloroform‐induced hepatotoxicity
1990 · L. Arthur Hewitt, Carol Palmason, et al. · Liver International · 18
The role of biotransformation–detoxication in acetone-, 2-butanone-, and 2-hexanone-potentiated chloroform-induced hepatotoxicity
1987 · L. Arthur Hewitt, Céline Valiquette, et al. · Canadian Journal of Physiology and Pharmacology · 18
Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data
2015 · Clément François, Robert A. Hauser, et al. · Journal of Medical Economics · 13
PDF
A randomized, placebo-controlled, phase 2 study of the efficacy and safety of droxidopa in patients with intradialytic hypotension
2015 · Mark D. Vannorsdall, Srinivas Hariachar, et al. · Postgraduate Medicine · 11
PDF
Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects
2018 · Jack J. Chen, L. Arthur Hewitt · Drugs in R&D · 8
PDF
Efficacy and Safety of CH-1504, a Metabolically Stable Antifolate, in Patients with Active Rheumatoid Arthritis: Results of a Phase II Multicenter Randomized Study
2011 · EDWARD C. KEYSTONE, VALERY S. SHIRINSKY, et al. · The Journal of Rheumatology · 8
PDF
Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment
2022 · Robert A. Hauser, Antonella Favit, et al. · Neurology and Therapy · 7
PDF
Impact of the Norepinephrine Prodrug Droxidopa on the QTc Interval in Healthy Individuals
2017 · William B. White, L. Arthur Hewitt, et al. · Clinical Pharmacology in Drug Development · 7
PDF
Use of droxidopa for the long-term treatment of neurogenic orthostatic hypotension
2018 · Satish R Raj, Lawrence Arthur Hewitt · European Heart Journal · 4
PDF
Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension
2016 · Clément François, Gerald J. Rowse, et al. · BMC Neurology · 4
PDF
A Call to Action: The Role of Healthcare Providers in Reducing the Burden Associated with Neurogenic Orthostatic Hypotension
2020 · Jessie S. Gibson, Christine B. Hunter, et al. · Neurology and Therapy · 3
PDF
Works count: 58
Citation count: 1,127
H-index: 16
I10-index: 18
Year
Topic
Type